Robert has over 45 years of experience in industries as diverse as finance, infrastructure and transportation. In 2001 he established Neuramatix Sdn Bhd as an R&D organization that has since expanded this across AI, advanced robotics and the life sciences. Viramatix is an initiative under the latter which already includes a publicly traded healthcare services company offering pathology and genetic screening services via medical practitioners in SE Asia.

Adlan's career began in the capital markets 20 years ago. As part of the Neuramatix group he engages directly with stakeholders on all fund raising, financial management and reporting activities. As part of this he retains strategic oversight of all legal and IP activities. Adlan was responsible for structuring the group's healthcare services business for IPO, and subsequent M&A activities as part of a long-term strategic plan. He has an MBA from the University of Strathclyde, United Kingdom.

Dr Rajik is an experienced drug discovery and early stage drug development scientist with extensive experience in peptide based drug discovery projects. He has an MSc in Bio-chemical Technology from Madurai Kamaraj University, India and a PhD in Molecular biology & Genetic engineering from UPM, Malaysia. After completing his doctoral studies in 2009, he joined Singapore General Hospital to work on the AON based therapeutics development for Amyotrophic Lateral Sclerosis, a progressive neuro-degenerative disease. In 2010, he joined Neuramatix's life science group to set up a drug discovery and development unit to explore anti-virals. This effort lead to the formation of Viramatix where he continues to oversee the entire drug discovery program.

Dr Schulz-Utermoehl has over 17 years' experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He has held senior roles at Shire, AstraZeneca and Merck. Prior to co-founding Polleo Pharma, Dr Schulz-Utermoehl was a Director within the Exploratory Projects Department for Shire Speciality Pharmaceuticals in the UK. Dr Schulz-Utermoehl carried out post-doctoral research at Novo Nordisk A/S, holds a PhD in Biochemistry from Imperial College London, an MSc in Toxicology from the Royal Postgraduate Medical School, London and a BSc in Pharmacology/Physiology from the University of Leeds.